LONDON – 3rd August 2021 Jupiter Life Sciences Consulting, a global leader in pricing and market access strategy in the biopharmaceutical industry, are delighted to announce the appointment of Catherine Beecher (Cathy) as Partner. Cathy will strengthen and help build the growing European team and provide...
On June 7th 2021, the FDA made a landmark decision in clearing Aduhelm under the accelerated approval pathway for Alzheimer's disease. As the first therapy approved in the category in nearly two decades, Aduhelm provides an option for patients with this highly debilitating disease; however,...
Between Now and the Post-Pandemic World Decades of speculation and misconceptions about vaccines have clouded the enormous contributions of vaccinations on global health. Researchers around the world have been racing to develop a safe and effective COVID-19 vaccine. Now that some have approved globally and more...
The Evolution of COVID-19 Therapeutics A chaotic COVID-19 patient journey has developed in the wake of responses from various stakeholders and the evolving pandemic. As a result of numerous conversations with relevant key stakeholders, this compendium explores the patient journey, challenges in treatment, the impact of...
COVID-19’s Impact on Oncology In response to COVID-19, global healthcare systems and life sciences research have been harnessed by the need to fight the public health crisis, ushering in enormous challenges in critical therapeutic areas as resources are diverted to address the pandemic. Cancer, with 18...
November 2020 In October 2020, UnitedHealthcare introduced an Accumulator Adjustment Medical Benefit Program, the first of its kind to be specific to the medical benefit [1]. Accumulator programs aim to leverage the copay assistance programs offered by the manufacturer, to prevent them from counting towards a...
Critical Challenges and Opportunities Even in non-pandemic times, rare and ultra-rare disease communities face staggering challenges as they work ceaselessly for awareness, support and treatment. It’s crucial to examine the impact of COVID-19 on rare diseases, which can help shed light on heightened hurdles as well...
Is it Time for Digital Health to Break Out of Isolation? The United States has been in an ongoing battle with substance addiction and opioid overdose, which has resulted in high rates of mortality; now with COVID-19, we are facing increased social isolation, more mental health...
In June 2020, the Health Resources and Services Administration (HRSA) reported that net purchasing volume under the 340B program in 2019 was at least $29.9 billion. This accounts for purchases made through wholesalers and excludes direct-from-manufacturer and some specialty distributor purchases – the total volume...
The opioid epidemic in the United States is a serious national crisis that affects public health as social and economic welfare. From 1999 to 2017, more than 700,000 people died from a drug overdose; of which, 218,000 were related to prescription opioid use/abuse.1 In 2017...